Showing posts with label polio vaccine. Show all posts
Showing posts with label polio vaccine. Show all posts

Thursday, April 24, 2025

The polio shot heard round the world

 

A son recalls his father’s great medical achievement

By 

Illustrations by Cristian Barba Camarena

I have been president of the Jonas Salk Legacy Foundation since its founding in 2009. As you can imagine, focusing my attention in that role on the legacy of my father’s many contributions to humanity — including his creation of the Salk Institute for Biological Studies, just up the road in La Jolla on a bluff overlooking California’s magnificent Pacific Coast — has a special significance for me.

My father, Dr. Jonas Salk, developer of the first polio vaccine, was born in New York City on 28 October 1914, exactly three months after the beginning of World War I. From his earliest days, he was someone who wanted to do something to be helpful to humanity. That impulse and drive may have come in part from an incident that was imprinted in his memory when he was a little boy. At the end of the war, on Armistice Day in 1918, he witnessed a parade filled with soldiers who had come home from battle. Some had been injured or maimed, walking with crutches or using a wheelchair. My father always had a sensitive side, and he was deeply affected by what he had seen.

As he grew older, my father considered going to law school and running for Congress. His mother, who had come over to this country from Russia, astutely advised him that this was not a good decision — especially since, as she put it, “you can’t even win an argument with me.” I think she wanted him to become a rabbi, which I don’t think was in my father’s character.

As it turned out, my father decided to go to City College in New York, and there his studies took an unexpected turn. In his first year, a chemistry course was offered, and this appealed to him. The problem was that the class met on a Saturday, the Jewish Sabbath. His parents were very

observant in following Jewish traditions and customs, which meant that my father had a difficult decision to make. In the end, he took the chemistry class, which was the starting point for what turned out to be a long and productive career.

After college, having had such a positive experience training in the sciences, my father enrolled in the New York University College of Medicine. From the start, he knew that he wanted to go into research. During a first-year micro-biology class, a professor spoke about vaccines. He explained that, though doctors could use chemically inactivated toxins to vaccinate against bacterial diseases such as diphtheria and tetanus, they could not use inactivated viruses to immunize against viral diseases such as influenza or polio because protection against infection with viruses required that the body experience an actual infection with the living virus.

That didn’t make any sense to my father, and when he asked his teacher why, the professor basically responded, “Well, just because.” That unsatisfactory answer set my father on a journey of discovery that would fulfill his dream to help humanity, in ways and to a degree that he could never have imagined. And it was a journey on which his family, including his three sons, would be carried along.

Following medical school, after a two-year clinical internship at New York’s Mount Sinai Hospital, my father went to work with Dr. Thomas Francis Jr., then the head of the epidemiology department at the University of Michigan. My father had previously worked with Dr. Francis on influenza while still a student at NYU College of Medicine, and that had been a seminal experience for him. Working alongside his mentor at Michigan, my father made important contributions to the successful creation of an influenza vaccine, utilizing a chemically inactivated virus, that was introduced for use by the Army at the end of World War II.

In 1947, seeking to head a laboratory of his own, my father moved on to the University of Pittsburgh School of Medicine. There he took charge of creating the Virus Research Laboratory and, with his growing interest in polio, received a grant for polio research from the National Foundation for Infantile Paralysis.

As all of this was going on, my father had married and started a family. He met my mother, Donna, while working one summer at the Marine Biological Laboratory in Woods Hole, Massachusetts. They married on 9 June 1939, the day after he graduated from medical school with an M.D. degree. I was born five years later, the first of my parents’ three sons. During my childhood, polio epidemics became an increasing global scourge. I can remember my parents not allowing us to visit a beloved amusement park when we were on vacation, out of fear of our becoming infected. On another occasion, our family accompanied my father to a polio meeting at the Greenbrier resort in West Virginia. There I saw a girl at a swimming pool who had been disabled by the disease. Because I was around the same age as the girl, that encounter had a lasting impact on me.

During all this time my father and his team were rigorously working to develop a vaccine that would be effective against all three immunologic types of polio. The first human studies with the experimental vaccine were conducted at the D.T. Watson Home for Crippled Children outside of Pittsburgh. These tests included children who had already experienced some form of paralysis due to polio. Because they had already been infected by at least one of the three types of poliovirus, there was no danger they could become paralyzed again if they were injected with the chemically inactivated virus of the same type. It turned out that when these children were injected with the inactivated virus, their antibodies against the virus were boosted. Since antibodies in the blood stream were all that was needed to prevent the virus from traveling to the brain and spinal cord and killing the nerve cells that control muscle movement, when that information was confirmed, my father knew that the vaccine he and his team had been working on should be a success.

At one point early on, my father had tested the experimental vaccine on himself and his lab workers. And one day it was our turn, me and my two brothers, ages 9, 6, and not quite 3 years old. As you can imagine, I was not very happy to be part of this joyful experience. Our father came home with the vaccine, and he proceeded to sterilize the daunting glass syringes and the metal needles by boiling them on the kitchen stove. I was absolutely not a fan of needles — but what child is? I stood there, miserable and looking out the window, my arm held out and awaiting the injection. And then something miraculous happened: I didn’t feel the needle. It didn’t hurt, unlike every other shot I’d ever had. And for that reason, that day is burnt into my memory forever.

Two years later, on 12 April 1955, my father joined Dr. Francis at a press conference at the University of Michigan. Dr. Francis had been tasked with analyzing the results of the vast clinical trial of the experimental vaccine, and now he made an announcement that would change medical history: The vaccine had been demonstrated to be up to 90 percent effective in preventing polio. Pandemonium broke loose. Kids were let out of school, church bells rang, factory whistles blew. The pall of fear that had pervaded this country for so many years was lifted. I get goose bumps thinking about it even all these years later.

In 1955, more than 10 million children received one or more injections of the Salk vaccine. Within one year, polio cases and deaths in the United States had been nearly halved, a trend that continued and made a vision of polio eradication a possibility.

Today, that goal is getting ever closer to reality. Rotary International has been a champion in ensuring that one day — and, I hope, one day soon — that goal will be reached. Rotary helped found the Global Polio Eradication Initiative, and it continues to put a major emphasis on getting the job done, as does the Gates Foundation, with its generous donations, and the other organizations that are part of the GPEI. Everyone is working unbelievably hard, and practical work is being done on the ground where it’s most essential. Efforts are underway to remove obstacles and deal with societal issues that have impeded progress in some remaining parts of the world.

The contributions Rotary has made toward eradicating polio have been indispensable, and its indomitable spirit has been a driving force in this effort. I’ve had the great pleasure on many occasions of speaking to and with members of Rotary, and each time it has been an uplifting experience. The desire shared by Rotary members to help the world is inspiring and mirrors the driving force in my father’s life.

My father was the author of several books. One of them, recently published in an updated version as A New Reality: Human Evolution for a Sustainable Future, he co-wrote with my brother Jonathan. Seeing that title, and the titles of the other books he wrote, provides insights into where my father’s interests and hopes lay. They also suggest where we should turn our efforts and energies next.

As my father did with polio, we need to go beyond theorizing. We can have grand desires for the human species, but we need to create and utilize real and useful tools that can have a direct impact on societal interactions and environmental imbalances. Humanity seems to be facing monumental problems, but they can be overcome. Just look at what my father accomplished. Seventy years ago, there was a vaccine in a bottle, and today we’re almost at the point of achieving a once unimaginable outcome.

I feel a devotion to my father, and I feel a responsibility to ensure that his ways of thinking and his contributions are fully understood. He embraced the entire world in his scientific, humanistic, and philosophical vision for the future, and the elements of his legacy will continue to reach into everyone’s lives.

Dr. Peter L. Salk is president of the Jonas Salk Legacy Foundation in La Jolla, California, and a part-time professor at the University of Pittsburgh School of Public Health.

This story originally appeared in the October 2024 issue of Rotary magazine.


Visit :-

https://www.rotary.org/en/polio-shot-heard-round-world


‘When,’ not ‘if’: Progress continues toward ending polio

 

On World Polio Day, Rotary International leaders and public health experts reiterate their commitment to global eradication

By 

Eradicating polio around the world is still an attainable goal, Rotary International President Stephanie A. Urchick and public health experts said as they commemorated World Polio Day in the city where the vaccine was developed.

“I know it is a question of when polio will be eradicated, not if,” Urchick told the audience at a livestream event on 24 October in Pittsburgh, Pennsylvania, USA. 

“Our Action Plan talks about improving our impact. That’s really where our polio eradication program shines,” Urchick added. “Millions of children won’t get this crippling disease. Billions of U.S. dollars won’t be spent on ancillary health care costs as a result of this disease. We have made so much progress.”

Rotary leaders, including RI President Stephanie Urchick (middle), and global health experts discuss the future of the polio eradication effort at a World Polio Day event in Pittsburgh, Pennsylvania, USA, 24 October 2024.

Photo credit: Rotary Zones 33/34

World Polio Day raises awareness and funds for the Global Polio Eradication Initiative’s work to eliminate the disease. Since Rotary and its partners formed the GPEI in 1988, the number of wild polio cases has decreased by 99.9%. The event highlighted Rotary’s continuing efforts toward complete eradication.

Polio remains endemic in two countries, Afghanistan and Pakistan. In 2024, increased case counts of wild poliovirus and the first case of paralytic polio in Gaza in 25 years served as a reminder that until the disease is fully eliminated everywhere, it remains a threat to children everywhere.

Despite the challenges, Michael K. McGovern, chair of the International PolioPlus Committee, said he remains confident as ever that global eradication is within reach. “We’re in a bumpy period, but we’re going to get this done by continuing to focus on Afghanistan and Pakistan and doing the things that were done so successfully by Rotarians,” he said.

The event included videos featuring polio vaccination workers in the field. Urchick said she was inspired by them during a visit to Karachi, Pakistan, earlier this year.

“Men work diligently to immunize thousands of children every day at traffic checkpoints, while women go house to house to reach families directly,” Urchick said. “Some workers literally climb mountains to vaccinate children in remote locations, and their determination never wavers.”

The livestream event was part of a two-day Rotary zone institute. RI Director Patrick Eakes, who convened the institute, said Pittsburgh was a perfect location because it’s where Dr. Jonas Salk developed the vaccine. “We realized we were in a unique position,” said Eakes, a member of the Rotary Club of Crescent (Greensboro), North Carolina, USA.

Dr. Peter L. Salk, president of the Jonas Salk Legacy Foundation in La Jolla, California, and a part-time professor at the University of Pittsburgh School of Public Health, talked about what drove his father to develop the first inactive polio vaccine.

“He just never let go,” Salk recalled. “It was his personality to have a dream and get things done.”

Salk said his father wanted to make a difference in the world from a young age and became interested in science. After working in the U.S. state of Michigan on an influenza vaccine, he came to Pittsburgh in 1947 to work at the virus research lab and received a grant for polio research from the National Foundation for Infantile Paralysis. That led to his work developing the inactive polio vaccine.

Other presenters at the livestream event included 2016-17 RI President John Germ. Several members of Rotary’s eradication effort also sent video messages.

In a video shown at the event that was originally recorded for the 2023 Rotary International Convention, Gates Foundation co-founder Bill Gates lauded the commitment toward eradication. “When polio is eradicated, it will be one of the biggest advances in public health in human history,” said Gates. The Gates Foundation, a partner in the GPEI, matches up to US$50 million that Rotary raises each year at a 2-to-1 ratio, which means up to US$150 million for the effort each year.

Salk, too, said he was honored to be in a room full of Rotary members who have a passion for solving tough problems.

“Every time I get together with Rotarians,” he said, “I am just uplifted by the quality of humanity that you all radiate and the dedication you put in all the different realms helping the world become a better place.”


Visit:-

https://www.rotary.org/en/when-not-if-progress-continues-toward-ending-polio